Exon Skipping

Illustration of DNA
Blog Post

FDA Accepts NS Pharma’s NDA for Viltolarsen for the Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | February 26, 2020
Featured Article

A Good Beginning: Newborn Screening

By Donna Albrecht | January 17, 2020
Illustration of DNA
Blog Post

FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | December 13, 2019
Blog Post

Five Questions with DMD Researcher Matthew Wood

By Jeanene Swanson | October 23, 2019
Blog Post

NS Pharma Submits New Drug Application to FDA for Viltolarsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | October 7, 2019
Illustration of DNA
Blog Post

Simply Stated: Is Muscular Dystrophy Genetic?

By Jeanene Swanson | August 5, 2019
Blog Post

Audentes Therapeutics Announces Plans to Develop Gene-Targeted Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

By Jeanene Swanson | April 11, 2019
Blog Post

Sarepta Therapeutics Announces Positive Interim Results from Study of Casimersen to Treat DMD Amenable to Exon 45 Skipping

By Jeanene Swanson | April 4, 2019
Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | March 1, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019